Nur Hamzeli̇
Nur Hamzeli̇ has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Bekir Kocazeybek
Department of Medical Microbiology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul 34320, Turkey
2 shared publications - Nesrin Gareayaghi
Sağlık Bilimleri Üniversitesi, Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi, Kan Merkezi, İstanbul
2 shared publications - Ahmet Aktaş
İstanbul University, İstanbul Faculty of Medicine, Medical Microbiology Department, İstanbul, Türkiye
1 shared publication - Fatma Köksal Çakırlar
Istanbul University-Cerrahpaşa Medical Faculty, Department of Medical Microbiology, Istanbul, Turkey
1 shared publication - Ferhat Osman Daşdemir
Department of Environmental Protection Technologies, Vocational School, Istanbul Arel University, Istanbul 34537, Turkey
1 shared publication - Harika Oyku Dinc
Department of Microbiology, Medical Faculty, Uskudar University, Istanbul 34662, Turkey
1 shared publication
Latest Publications
- 21 April 2026
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 60 (2) , 177-187
Okült HBV Enfeksiyonunda ve Düşük Düzey HBsAg Pozitifliğinde Yeni Nesil HBsAg Testinin Konvansiyonel Yöntemle Karşılaştırmalı Değerlendirilmesi
This study aimed to comparatively evaluate the conventional hepatitis B surface antigen (HBsAg) assay and the next-generation HBsAg NEXT (HBsAgNx) assay in samples with low-level HBsAg positivity and in cases of occult hepatitis B infection (OBI). A total of 497 individuals were included in the study, comprising 300 individuals with low-level HBsAg positivity, 100 OBI cases (64 seropositive and 36 seronegative) and 97 healthy controls. Serum samples were analyzed using the Abbott ARCHITECT HBsAg Qualitative II assay (Abbott Diagnostics, Wiesbaden, Germany) and the Abbott Alinity i HBsAg NEXT assay (Abbott Diagnostics, Wiesbaden, Germany). The presence of HBV DNA was confirmed by real-time polymerase chain reaction (Rt-PCR) using the COBAS AmpliPrep/COBAS TaqMan HBV test v2.0 (Roche Diagnostics, Mannheim, Germany). HBV DNA (Rt-PCR) was accepted as the gold standard reference for diagnostic performance evaluation. To minimize potential bias arising from sample selection, individuals with lowlevel HBsAg positivity and OBI cases were analyzed separately. In the low-level HBsAg-positive group, semi-quantitative S/CO values of the assays were compared, whereas in the OBI group, only the detection rates of HBV DNA-positive cases were evaluated. A total of 17 OBI cases (17%) were identified that were tested negative by the conventional assay but positive by the HBsAgNx assay. Differences between the assays were evaluated using the McNemar test and p< 0.05 was considered statistically significant. Median values obtained with the HBsAgNx assay were significantly higher than those obtained with the conventional assay (p< 0.001). The HBsAgNx assay provides clinically significant contributions particularly in the OBI group, by detecting cases that cannot be identified by conventional assays. These findings indicate that the integration of high-sensitivity HBsAg assays into current HBV diagnostic algorithms would increase case detection and contribute to both transfusion safety and the clinical management of OBI.
- 21 April 2026
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 60 (2) , 177-187
Okült HBV Enfeksiyonunda ve Düşük Düzey HBsAg Pozitifliğinde Yeni Nesil HBsAg Testinin Konvansiyonel Yöntemle Karşılaştırmalı Değerlendirilmesi
This study aimed to comparatively evaluate the conventional hepatitis B surface antigen (HBsAg) assay and the next-generation HBsAg NEXT (HBsAgNx) assay in samples with low-level HBsAg positivity and in cases of occult hepatitis B infection (OBI). A total of 497 individuals were included in the study, comprising 300 individuals with low-level HBsAg positivity, 100 OBI cases (64 seropositive and 36 seronegative) and 97 healthy controls. Serum samples were analyzed using the Abbott ARCHITECT HBsAg Qualitative II assay (Abbott Diagnostics, Wiesbaden, Germany) and the Abbott Alinity i HBsAg NEXT assay (Abbott Diagnostics, Wiesbaden, Germany). The presence of HBV DNA was confirmed by real-time polymerase chain reaction (Rt-PCR) using the COBAS AmpliPrep/COBAS TaqMan HBV test v2.0 (Roche Diagnostics, Mannheim, Germany). HBV DNA (Rt-PCR) was accepted as the gold standard reference for diagnostic performance evaluation. To minimize potential bias arising from sample selection, individuals with lowlevel HBsAg positivity and OBI cases were analyzed separately. In the low-level HBsAg-positive group, semi-quantitative S/CO values of the assays were compared, whereas in the OBI group, only the detection rates of HBV DNA-positive cases were evaluated. A total of 17 OBI cases (17%) were identified that were tested negative by the conventional assay but positive by the HBsAgNx assay. Differences between the assays were evaluated using the McNemar test and p< 0.05 was considered statistically significant. Median values obtained with the HBsAgNx assay were significantly higher than those obtained with the conventional assay (p< 0.001). The HBsAgNx assay provides clinically significant contributions particularly in the OBI group, by detecting cases that cannot be identified by conventional assays. These findings indicate that the integration of high-sensitivity HBsAg assays into current HBV diagnostic algorithms would increase case detection and contribute to both transfusion safety and the clinical management of OBI.
- 15 March 2025
- Published by Elsevier in Microbial Pathogenesis
- Vol. 203, 107488
Isolation and characterization a novel Acinetobacter bacteriophage with activity against several multidrug-resistant Gram-negative bacteria
- 15 March 2025
- Published by Elsevier in Microbial Pathogenesis
- Vol. 203, 107488
Isolation and characterization a novel Acinetobacter bacteriophage with activity against several multidrug-resistant Gram-negative bacteria
- Open Access
- 25 September 2022
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 5 (5) , 1246-1251
Six-year seroprevalence results for blood center mandatory donor screenings: single center experience
Aims: Infections transmitted through blood and blood product transfusions are one of the most important health problems today. In Turkey; Microbiological screening for hepatitis B, hepatitis C, syphilis and HIV infections is mandatory for each unit of blood and blood components prepared for transfusion, regardless of the time between donations. In this study, it was aimed to determine the prevalence of HBV, HCV, HIV and syphilis in blood donors who applied to our Blood Center and to compare them with the prevalences in other regions of Turkey. Material and Method: The study was conducted between January 2016 and June 2022 and included 68195 donors. Screenings for HBsAg, anti-HCV, anti-HIV and syphilis tests were performed with commercial kits using the Electro-Chemiluminescence Immunoassay (ECLIA) principle. Positive results were confirmed by validation studies. Results: As a result of screening, 279 (0.4%) of 68195 donors tested positive for HBsAg, 56 (0.08%) for anti-HCV, 25 for anti-HIV (0.03%) and 197 (0.28%) for syphilis. Of the total donors, 2129 (3.1%) were volunteers and 66,066 (97%) were non-volunteer relatives. In total, 0.8% of the donors were positive for screening. Conclusion: The significant (0.8%) positivity detected in the HBsAg, anti-HCV, anti-HIV and syphilis tests of the donors showed that blood transfusion screening tests were vital. In addition, considering the window period of infections and the pre-seroconversion period, it was concluded that there is a need for methods with high sensitivity and solutions such as avoiding unnecessary transfusions.
- 25 September 2022
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 5 (5) , 1246-1251
Open AccessSix-year seroprevalence results for blood center mandatory donor screenings: single center experience
Aims: Infections transmitted through blood and blood product transfusions are one of the most important health problems today. In Turkey; Microbiological screening for hepatitis B, hepatitis C, syphilis and HIV infections is mandatory for each unit of blood and blood components prepared for transfusion, regardless of the time between donations. In this study, it was aimed to determine the prevalence of HBV, HCV, HIV and syphilis in blood donors who applied to our Blood Center and to compare them with the prevalences in other regions of Turkey. Material and Method: The study was conducted between January 2016 and June 2022 and included 68195 donors. Screenings for HBsAg, anti-HCV, anti-HIV and syphilis tests were performed with commercial kits using the Electro-Chemiluminescence Immunoassay (ECLIA) principle. Positive results were confirmed by validation studies. Results: As a result of screening, 279 (0.4%) of 68195 donors tested positive for HBsAg, 56 (0.08%) for anti-HCV, 25 for anti-HIV (0.03%) and 197 (0.28%) for syphilis. Of the total donors, 2129 (3.1%) were volunteers and 66,066 (97%) were non-volunteer relatives. In total, 0.8% of the donors were positive for screening. Conclusion: The significant (0.8%) positivity detected in the HBsAg, anti-HCV, anti-HIV and syphilis tests of the donors showed that blood transfusion screening tests were vital. In addition, considering the window period of infections and the pre-seroconversion period, it was concluded that there is a need for methods with high sensitivity and solutions such as avoiding unnecessary transfusions.